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Background.  —  Controlling  low-density  lipoprotein  (LDL)-cholesterol  concentration  is  of  tremen-
dous importance  to  reduce  cardiovascular  risk.
Aims.  —  To  investigate  the  attainment  of  LDL-cholesterol  targets  recommended  in  French  and
European  guidelines  on  cardiovascular  prevention,  according  to  levels  of  cardiovascular  risk.
Abbreviations: CHD, coronary heart disease; EAS, European Atherosclerosis Society; eGFR, estimated glomerular ﬁltration rate; ESC,
European Society of Cardiology; HDL, high-density lipoprotein; LDL, low-density lipoprotein; MONA LISA, MOnitoring NAtionaL du rISque
Artériel; MONICA, MONItoring of trends and determinants in CArdiovascular disease; SCORE, Systematic Coronary Risk Evaluation.
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Methods.  —  Participants  aged  35  to  74  years  (n  =  4609)  were  randomly  selected  from  the  general
population  of  three  French  regions.  A  standardized  data  collection  was  performed  to  assess
cardiovascular  risk  as  described  in  the  French  and  European  guidelines.
Results.  —  Overall,  17.5%  of  participants  were  considered  to  be  at  high  risk  and  25.4%  at  high
or very  high  risk,  according  to  the  French  and  European  guidelines,  respectively.  Only  1.2%  of
participants  with  no  cardiovascular  risk  factors  according  to  the  French  guidelines  had  an  LDL-
cholesterol  concentration  above  the  recommended  target,  whereas  82.5%  of  high-risk  subjects
did not  attain  their  goal  (70.8%  among  high-risk  subjects  receiving  lipid-lowering  therapy).
Among untreated  people,  the  median  reduction  in  LDL-cholesterol  needed  to  reach  target
ranged from  6.6%  (lowest-risk  groups)  to  36.0%  (highest-risk  subjects).  When  risk  was  classiﬁed
according  to  the  European  guidelines,  the  majority  of  participants  did  not  reach  the  recom-
mended  LDL-cholesterol  targets,  irrespective  of  their  level  of  risk  or  lipid-lowering  therapy.
Conclusion.  —  In  a  majority  of  primary  prevention  candidates  with  multiple  risk  factors  and
in most  high-risk  subjects,  LDL-cholesterol  targets  recommended  by  French  guidelines  are  not
being achieved,  either  because  of  insufﬁcient  treatment  or  because  subjects  are  not  recognized
as being  at  risk.  More  stringent  targets  proposed  by  the  European  guidelines  are  not  being
achieved in  most  cases.
© 2012  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé
Contexte.  — Le  contrôle  du  cholestérol-LDL  est  primordial  pour  réduire  le  risque  cardiovascu-
laire.
Objectifs.  — Décrire  l’atteinte  des  objectifs  ﬁxés  par  les  recommandations  franc¸aises  et  euro-
péennes pour  le  cholestérol-LDL,  en  fonction  du  niveau  de  risque  cardiovasculaire.
Méthodes.  — Les  participants,  âgés  de  35  à  74  ans  (n  =  4609)  ont  été  tirés  au  sort  dans  la
population  générale  de  trois  régions  franc¸aises.  Un  recueil  de  données  standardisé  a  été
effectué  pour  déterminer  le  niveau  de  risque  cardiovasculaire,  tel  que  décrit  dans  les  recom-
mandations  franc¸aises  et  européennes.
Résultats.  — L’échantillon  comprenait  17,5  %  de  participants  à  haut  risque  (recommandations
franc¸aises) et  25,4  %  de  sujets  à  haut  ou  très  haut  risque  (recommandations  européennes).
Seulement  1,2  %  des  participants  sans  facteur  de  risque  (recommandations  franc¸aises)  avaient
un taux  de  cholestérol-LDL  au-dessus  de  l’objectif.  En  revanche,  82,5  %  des  sujets  à  haut  risque
n’étaient pas  à  l’objectif  (70,8  %  des  sujets  à  haut  risque  sous  traitement  hypolipémiant).
Parmi les  sujets  non  traités,  la  réduction  médiane  de  cholestérol-LDL  nécessaire  pour  atteindre
l’objectif, variait  de  6,6  %  (sujets  les  moins  à  risque)  à  36,0  %  (haut  risque).  Lorsque  le  risque
était déﬁni  selon  les  critères  européens,  la  majorité  des  participants  n’atteignait  pas  l’objectif,
qu’il y  ait  ou  non  prise  d’un  traitement  hypolipémiant.
Conclusion.  —  La  majorité  des  sujets  à  haut  risque  ou  cumulant  les  facteurs  de  risque  n’est
pas à  l’objectif,  soit  du  fait  d’un  traitement  insufﬁsant,  soit  parce  que  les  sujets  ne  sont  pas
identiﬁés comme  étant  à  risque.  Cela  est  encore  plus  marqué  si  l’on  considère  les  objectifs  des
recommandations  européennes.
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ackground
urrent  guidelines  for  the  prevention  and  treatment  of  car-
iovascular  disease  emphasize  the  importance  of  treating
ultiple  risk  factors,  including  dyslipidaemia  and  hyper-
ension,  depending  on  the  patient’s  overall  level  of  risk
1—3].  This  approach  is  also  recommended  in  the  most
ecent  evidence-based  review  on  dyslipidaemia  manage-
ent  from  the  French  health  agency  (Haute  Autorité  de
anté)  [4].  The  potential  impact  of  lipid-lowering  therapy
n  the  prevalence  of  dyslipidaemia  in  France  has  been  high-
ighted  by  epidemiological  data  from  the  MONItoring  of
rends  and  determinants  in  CArdiovascular  disease  (MONICA)
roject,  which  were  obtained  in  1996—1997,  and  the  MONA
ISA  (MOnitoring  NAtionaL  du  rISque  Artériel)  survey,  which
i
m
o
[s  droits  réservés.
as  conducted  between  2006  and  2007  [5].  These  stud-
es  showed  signiﬁcant  decreases  in  low-density  lipoprotein
LDL)-cholesterol  concentrations  and  dyslipidaemias  over  a
0-year  period,  concurrent  with  the  increasing  use  of  lipid-
owering  therapy,  particularly  statins  [5].
Despite  the  existence  of  numerous  national  and  inter-
ational  guidelines  for  the  management  of  dyslipidaemia,
everal  studies  have  shown  that  management  is  often  subop-
imal  in  Europe  [6,7]. Besides,  prevalence  of  cardiovascular
isk  factors  is  still  substantially  elevated  in  France  [5,8—11].
he  aim  of  this  analysis  from  the  MONA  LISA  study  was  to
nvestigate,  in  the  French  general  population,  the  attain-
ent  of  LDL-cholesterol  targets  in  subjects  at  various  levels
f  cardiovascular  risk,  as  deﬁned  in  the  most  recent  French
4]  and  European  [2]  guidelines.
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2Attainment  of  LDL-cholesterol  target  
Methods
Details  of  the  MONA  LISA  survey  have  been  published  pre-
viously  [5,8—11].  Participants  aged  35  to  74  years  were
recruited  between  2006  and  2007  from  the  general  popula-
tion  in  three  regions  of  France:  the  Lille  urban  community  in
Northern  France,  the  Bas-Rhin  department  in  Eastern  France
and  the  Haute-Garonne  department  in  South  West  France.
The  participants  were  selected  randomly  from  electoral  rolls
after  stratiﬁcation  by  town  size,  sex  and  age,  in  order  to
achieve  a  sample  size  of  200  of  each  sex  in  each  age  group
(35—44  years,  45—54  years,  55—64  years,  65—74  years)  and
each  region.  In  accordance  with  French  law,  the  study  pro-
tocol  was  approved  by  the  appropriate  independent  ethics
committee  and  written  informed  consent  was  obtained  from
all  participants.
Included  subjects  responded  to  a  standardized  ques-
tionnaire,  covering  demographic  variables,  socioeconomic
status,  medical  history  and  drug  intake,  and  under-
went  a  standardized  physical  examination.  Blood  pressure
was  measured  twice,  at  rest,  with  a  standard  sphyg-
momanometer  (OMRON® 705IT).  A  20  mL  blood  sample
was  collected  into  a  disodium  ethylene-diamine-tetraacetic
acid  tube  after  an  overnight  fast  (at  least  10  h)  and
plasma  was  separated  by  centrifugation  within  4  h.  Choles-
terol  and  triglyceride  concentrations  were  measured  by
enzymatic  assays  (Olympus,  Melville,  NY,  USA),  and  glu-
cose  was  measured  by  the  standard  glucose  hexokinase
assay  (DuPont  Dimension,  Brussels,  Belgium).  High-density
lipoprotein  (HDL)-cholesterol  was  assessed  after  sodium
phosphotungstate/magnesium  chloride  precipitation  (Olym-
pus);  LDL-cholesterol  was  determined  by  the  Friedewald
equation  if  triglyceride  concentrations  were  less  than
4.6  mmol/L  (4  g/L).  All  biological  measurements  were  per-
formed  in  a  core  laboratory  (Institut  Pasteur  de  Lille).
Assessment of  cardiovascular risk
For  each  participant,  the  presence  of  cardiovascular  risk
factors  (family  history  of  premature  coronary  heart  disease
[CHD],  hypertension,  smoking,  dyslipidaemia  or  diabetes)
was  recorded  and  the  global  cardiovascular  risk  was  cal-
culated  using  established  scoring  systems  [2—4,12,13]. A
family  history  of  premature  CHD  was  deﬁned  as  the  occur-
rence  of  a  myocardial  infarction  in  the  participant’s  father
before  the  age  of  55  years  or  in  the  participant’s  mother
before  65  years.  Smoking  referred  to  current  smoking
(any  type  of  smoking:  cigarettes,  cigars,  pipe)  or  past
smoking  stopped  within  the  previous  3  years.  Hyperten-
sion  was  deﬁned  as  a  resting  blood  pressure  of  greater
or  equal  to  140/90  mmHg  (mean  of  two  measurements)
or  greater  or  equal  to  130/80  mmHg  among  people  with
diabetes  or  an  estimated  glomerular  ﬁltration  rate  (eGRF)
less  than  60  mL/min/1.73  m2 (evaluated  by  the  Modiﬁcation
of  Diet  in  Renal  Disease  formula)  or  the  use  of  antihy-
pertensive  medications.  Hypercholesterolaemia  was  deﬁned
as  an  LDL-cholesterol  concentration  greater  or  equal  to
4.1  mmol/L  (1.6  g/L)  or  the  use  of  lipid-lowering  medica-
tion  with  triglyceride  concentration  less  than  1.7  mmol/L
(1.5  g/L);  hypertriglyceridaemia  or  combined  dyslipidaemia
were  deﬁned  as  triglyceride  concentration  greater  or  equal
to  1.70  mmol/L  (1.5  g/L)  and  low  HDL-cholesterol  was
E
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eﬁned  as  a  concentration  less  than  1  mmol/L  (0.4  g/L).
iabetes  was  deﬁned  as  a  fasting  blood  glucose  concentra-
ion  greater  or  equal  to  7  mmol/L  (1.26  g/L)  or  the  use  of
ypoglycaemic  drug  treatment.
The  10-year  risk  of  CHD  (corresponding  to  the  probabil-
ty  of  a  given  subject  developing  CHD  in  the  next  10  years)
as  calculated  using  the  Framingham  algorithm  [13]  and  the
0-year  risk  of  fatal  cardiovascular  disease  (death  caused
y  any  arterial  disease,  including  coronary,  cerebrovascular
nd  other  artery  diseases,  and  sudden  death)  was  estimated
sing  the  Systematic  Coronary  Risk  Evaluation  (SCORE)  sys-
em  [12].
The level  of  risk  was  also  scored  according  to  the
rench  guidelines,  based  on  the  number  of  risk  factors
resent  [4].  These  risk  factors  were:  age  (≥  50  years  in  men
nd  ≥  60  years  in  women),  family  history  of  premature  CHD,
urrent  or  past  smoking  as  deﬁned  above,  hypertension,  dia-
etes  and  low  HDL-cholesterol.  The  total  number  of  risk
actors  was  reduced  by  one  if  the  HDL-cholesterol  concen-
ration  was  greater  than  1.6  mmol/L  (0.6  g/L).  Subjects
ere  considered  to  be  at  high  risk  if  they  had  documented
ardiovascular  disease  (coronary  heart  disease,  cerebrovas-
ular  disease,  aortic  aneurysm  or  atherosclerosis  affecting
he  aorta  or  leg  arteries),  diabetes  and  eGFR  less  than
0  mL/min/1.73  m2 or  diabetes  with  at  least  two  other  risk
actors  or  a  10-year  risk  of  CHD  of  at  least  20%.
The  level  of  risk  was  also  estimated  according  to  the  2012
uidelines  for  cardiovascular  prevention  from  the  European
ociety  of  Cardiology  (ESC)  [2].  Subjects  were  considered
o  be  at  low  risk  if  their  SCORE  rating  was  less  than
%  (corresponding  to  a  10-year  probability  of  cardiovascu-
ar  mortality  of  less  than  1%),  and  they  were  categorized
t  moderate  risk  if  SCORE  was  greater  or  equal  to  1%
nd  less  than  5%.  Subjects  with  markedly  elevated  sin-
le  risk  factors  (arterial  blood  pressure  greater  or  equal
o  180/110  mmHg  or  LDL-cholesterol  greater  or  equal  to
.7  mmol/L  [2.2  g/L])  were  categorized  at  high  risk,  as  well
s  those  with  diabetes  (without  associated  cardiovascular
isk  factors),  moderate  chronic  kidney  disease  (eGFR  ran-
ing  between  30  and  59  mL/min/1.73  m2),  or  a  SCORE  rating
reater  or  equal  to  5%  and  less  than  10%.  Subjects  at  very
igh  risk  were  those  with  documented  cardiovascular  dis-
ase  (as  detailed  above),  severe  chronic  kidney  disease
eGFR  less  than  30  mL/min/1.73  m2),  diabetes  with  one  or
ore  associated  cardiovascular  risk  factor(s),  diabetes  with
GFR  less  than  60  mL/min/1.73  m2 or  subjects  with  a  SCORE
ating  greater  or  equal  to  10%.
argets for LDL-cholesterol according to levels
f cardiovascular risk
ccording  to  French  guidelines  [4],  LDL-cholesterol  should
e  less  than  5.7  mmol/L  (2.2  g/L)  in  subjects  with  no  associ-
ted  risk  factors,  less  than  4.9  mmol/L  (1.9  g/L),  4.1  mmol/L
1.6  g/L),  and  3.4  mmol/L  (1.3  g/L)  in  those  with  one,  two
nd  three  associated  risk  factors,  respectively,  and  less  than
.6  mmol/L  (1.0  g/L)  in  high-risk  subjects.  According  to  the
SC  guidelines  [2],  targets  for  LDL-cholesterol  are  3  mmol/L
1.15  g/L)  in  people  at  low  or  moderate  risk,  2.6  mmol/L
1.0  g/L)  in  those  at  high  risk  and  1.8  mmol/L  (0.7  g/L)  in
ubjects  at  very  high-risk.
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tatistical analysis
ontinuous  variables  were  summarized  as  mean  ±  standard
eviation  or  median  (interquartile  range)  for  non-normally
istributed  variables.  Categorical  variables  were  presented
s  absolute  numbers,  with  percentages  and  95%  conﬁ-
ence  intervals.  The  percentage  of  subjects  in  whom
DL-cholesterol  targets  were  not  achieved  was  estimated
n  the  overall  sample  and  subsequently  in  participants  who
ere  and  were  not  receiving  lipid-lowering  therapy.  In  the
verall  sample,  this  percentage  was  also  estimated  after
irect  standardization,  using  the  2009  French  population
o  provide  a  reference  distribution  for  age  and  sex.  The
ercentage  reduction  required  to  meet  the  LDL-cholesterol
arget  in  a  given  subject  was  calculated  as:
LDL-cholesterol −  LDL-cholesterol  target
LDL-cholesterol  level
×  100
All  analyses  were  performed  with  SAS® software  (SAS
nstitute,  Cary,  NC,  USA),  except  for  standardized  estimates,
hich  were  computed  with  STATA® software  (STATA  Corpo-
ation,  College  Station,  TX,  USA).
esults
tudy population
articipation  rates  in  the  MONA  LISA  study  were  50%  for
en  and  51%  for  women,  resulting  in  a  total  of  4769  par-
icipants  aged  35  to  74  years,  of  whom  4609  were  included
n  the  present  analysis.  Overall,  160  participants  (3.4%)  were
xcluded:  LDL-cholesterol  could  not  be  estimated  in  56  sub-
ects  because  triglyceride  concentrations  were  greater  or
qual  to  4.6  mmol/L  (4  g/L),  26  subjects  provided  a  non-
asting  blood  sample  and  data  on  cardiovascular  risk  factors
ere  missing  in  78  subjects.
Demographic  characteristics,  cardiovascular  risk  factors
nd  global  levels  of  cardiovascular  risk  for  the  included
articipants  are  summarized  in  Table  1.  Approximately
0%  of  the  participants  were  hypertensive  and  53.6%  had
ypercholesterolaemia,  hypertriglyceridaemia  or  combined
yslipidaemia.  The  mean  LDL-cholesterol  in  the  overall  pop-
lation  was  3.63  ±  0.91  mmol/L  (1.41  ±  0.35  g/L).  In  total,
46  subjects  were  receiving  treatment  with  lipid-lowering
rugs;  of  these,  78.4%  received  a  statin,  19.1%  a  ﬁbrate  and
.5%  were  treated  with  another  lipid-lowering  therapy.  A
otal  of  1615  subjects  (35.0%)  had  no  associated  cardiovas-
ular  risk  factors  (i.e.  no  risk  factors  except  possibly  high
DL-cholesterol,  as  deﬁned  in  the  French  guidelines  [4]),
ut  178  (3.9%)  had  three  or  more  associated  risk  factors  and
08  (17.5%)  were  considered  to  be  at  high  risk.  Similarly,
hen  risk  was  assessed  according  to  the  ESC  guidelines  [2],
4.1%  and  11.3%  were  considered  to  be  at  high  or  very  high
isk,  respectively.  The  median  10-year  risks  of  CHD  and  fatal
ardiovascular  disease  were  7.5%  and  0.60%,  respectively.ttainment of LDL-cholesterol goals
he  proportion  of  participants  not  attaining  the  rec-
mmended  LDL-cholesterol  target  concentration  varied
r
n
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ccording  to  the  level  of  cardiovascular  risk  deﬁned  in  the
rench  guidelines  (Table  2).  Among  participants  with  no
ssociated  cardiovascular  risk  factors,  almost  all  had  LDL-
holesterol  concentrations  below  the  recommended  target
oncentration  (<  5.7  mmol/L,  2.2  g/L).  However,  the  pro-
ortion  of  participants  in  whom  targets  were  not  achieved
ncreased  progressively  with  the  number  of  risk  factors
resent.  Among  the  subjects  at  highest  risk,  the  recom-
ended  LDL-cholesterol  target  (<  2.6  mmol/L,  1.0  g/L),  was
ot  achieved  in  82.5%  (92.3%  of  those  who  were  not  receiv-
ng  lipid-lowering  therapy  and  70.8%  of  those  who  were).
mong  these  high-risk  subjects,  analyses  were  stratiﬁed  to
istinguish  between  people  in  secondary  cardiovascular  pre-
ention  and  those  at  high  risk  but  in  primary  prevention  (i.e.
ubjects  with  diabetes  and  eGFR  less  than  60  mL/min/1.73
2, subjects  with  diabetes  and  at  least  two  other  risk  factors
r  subjects  with  a  10-year  risk  of  CHD  of  greater  or  equal  to
0%  but  without  documented  cardiovascular  disease).  The
roportion  of  participants  not  reaching  LDL-cholesterol  tar-
et  was  87.1%  in  high-risk  primary  prevention  subjects  but
as  signiﬁcantly  lower  (68.7%)  in  secondary  prevention  sub-
ects  (P  less  than  0.0001  for  2 test).
When  participants’  cardiovascular  risk  was  classiﬁed
ccording  to  the  ESC  guidelines  [2],  the  majority  of
articipants  did  not  reach  the  LDL-cholesterol  targets  rec-
mmended  in  those  guidelines,  irrespective  of  their  level  of
isk  or  lipid-lowering  therapy.  Approximately  three-quarters
f  participants  at  lowest  risk  did  not  reach  the  recommended
DL-cholesterol  target  of  less  than  3  mmol/L  (1.15  g/L),
hile  95.8%  of  those  at  very  high  risk  did  not  reach  the  more
tringent  target  of  less  than  1.8  mmol/L  (0.7  g/L)  (Table  2).
Tables  3  and  4  show  the  reductions  in  LDL-cholesterol
eeded  to  reach  the  recommended  LDL-cholesterol  tar-
ets  in  those  participants  in  whom  these  targets  were  not
chieved.  Among  the  participants  who  were  not  receiving
ipid-lowering  therapy,  the  mean  LDL-cholesterol  concen-
rations  ranged  from  6.23  ±  0.65  mmol/L  (2.41  ±  0.25  g/L)  in
articipants  with  no  associated  risk  factors  according  to  the
rench  guidelines  to  4.02  ±  0.47  mmol/L  (1.56  ±  0.18  g/L)
nd  4.06  ±  0.82  mmol/L  (1.57  ±  0.32  g/L)  in  those  at  the
ighest  levels  of  risk.  The  median  percentage  reduction  in
DL-cholesterol  needed  to  reach  the  targets  recommended
n  the  French  guidelines  ranged  from  6.6%  in  the  lowest-risk
roups  to  36.0%  in  subjects  with  the  highest  risk  (Table  3).
he  great  majority  of  participants  with  three  associated
isk  factors  or  fewer  required  reductions  of  less  than  30%
o  reach  their  LDL-cholesterol  target,  whereas  52.7%  of  the
articipants  at  high  risk  required  reductions  of  30  to  49%  and
.8%  required  reductions  of  greater  or  equal  to  50%  (Table  3).
Mean  LDL-cholesterol  concentrations  ranged  from  3.69
o  4.27  mmol/L  (1.43  to  1.65  g/L)  in  untreated  participants
t  all  levels  of  risk  according  to  the  ESC  guidelines  and  the
edian  LDL-cholesterol  reductions  needed  to  reach  the  tar-
ets  recommended  in  these  guidelines  increased  from  21.7%
n  participants  at  low  risk  to  50.2%  in  those  at  very  high
isk.  All  participants  at  low  or  moderate  risk  required  LDL-
holesterol  reductions  of  less  than  50%  to  reach  their  target,
hereas  50.2%  of  participants  at  very  high  risk  required
eductions  of  greater  or  equal  to  50%  (Table  3).
Similar  trends  were  seen  in  participants  who  did
ot  reach  their  LDL-cholesterol  target  despite  receiving
ipid-lowering  therapy  (Table  4).  In  these  participants,
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Table  1  Demographic  characteristics,  cardiovascular  risk  factors  and  levels  of  cardiovascular  risk  (n  =  4609)a.
Characteristic/risk  factor/level  of  risk
Age  (years)  55.3  ±  11.1
Men/women  2308/2301  (50.1/49.9)
Family  history  of  premature  CHD 271  (5.9)
Smoking 1005  (21.8)
Diabetes 318  (6.9)
Hypertension  2302  (49.9)
Systolic  blood  pressure  (mmHg)  134.4  ±  20.6
Diastolic  blood  pressure  (mmHg)  81.3  ±  10.7
Hypercholesterolaemia  1443  (31.3)
Hypertriglyceridaemia/combined  dyslipidaemia  1028  (22.3)
Low  HDL-cholesterol  442  (9.6)
Total  cholesterol  (mmol/L;  g/L)  5.71  ±  1.02;  2.21  ±  0.39
Triglycerides  (mmol/L;  g/L)  1.15  (0.85—1.63);  1.01  (0.74—1.43)
HDL-cholesterol  (mmol/L;  g/L)  1.48  ±  0.36;  0.57  ±  0.14
LDL-cholesterol  (mmol/L;  g/L)  3.63  ±  0.91;  1.41  ±  0.35
Fasting  blood  glucose  (mmol/L;  g/L)  5.22  (4.88—5.72);  0.94  (0.88—1.03)
Haemoglobin  A1c  (%)  5.48  ±  0.64
Level  of  risk  according  to  French  guidelines  [4]
No  associated  risk  factorsb 1615  (35.0)
1  associated  risk  factorb 1248  (27.1)
2  associated  risk  factorsb 760  (16.5)
≥  3  associated  risk  factorsb 178  (3.9)
High  risk  808  (17.5)
Level  of  risk  according  to  ESC  guidelines  [2]
Low  2364  (51.3)
Moderate  1075  (23.3)
High  650  (14.1)
Very  high  520  (11.3)
10-year  risk  of  CHD  (%)  [13]  7.5  (4.1—13.0)
10-year  risk  of  fatal  CVD  (%)  [12]  0.60  (0.16—1.92)
Data are number (%), mean ± standard deviation or median (interquartile range). CHD: coronary heart disease; CVD: cardiovascular
disease; ESC: European Society of Cardiology; HDL: high-density lipoprotein; LDL: low-density lipoprotein.
a See text for deﬁnitions of risk factors and risk assessments.
b ‘‘Associated’’: number of risk factors except high LDL-cholesterol, as deﬁned in the French guidelines [4].
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participants  at  the  highest  levels  of  risk,  whether  assessed
according  to  the  French  or  the  ESC  guidelines.  Among  par-
ticipants  with  0—3  associated  risk  factors  according  to  the
French  guidelines,  a  very  large  majority  required  reductions
of  less  than  30%  in  LDL-cholesterol  to  reach  their  recom-
mended  targets.  The  required  reduction  was  larger  among
high-risk  subjects  since  almost  one  third  needed  a  30  to  49%
reduction.  When  ESC  criteria  were  applied,  48.8%  of  par-
ticipants  at  very  high  risk  needed  a  30  to  49%  reduction  in
LDL-cholesterol  and  19.0%  a  reduction  of  greater  or  equal  to
50%  (Table  4).
Discussion
Recent  years  have  seen  favourable  trends  towards  decreases
in  total  and  LDL-cholesterol  concentrations  in  France  [5]  and
other  European  countries  [14,15]  and  in  the  USA  [16,17].
Despite  these  encouraging  trends,  however,  the  results  of
the  present  study  show  that  dyslipidaemia  remains  poorly
B
p
p
uontrolled  in  France.  A  high  proportion  of  primary  preven-
ion  candidates  and  an  even  higher  proportion  of  people
t  high  cardiovascular  risk  do  not  meet  either  the  LDL-
holesterol  targets  recommended  in  the  French  guidelines  or
he  more  stringent  targets  recommended  in  the  ESC  guide-
ines.
This  study  formed  part  of  the  MONICA  project,  which  has
een  monitoring  cardiovascular  risk  factors  in  France  and
ther  European  countries  since  1985  [5,18]. Most  centres
articipating  in  this  project  have  subsequently  stopped  col-
ecting  data  because  of  ﬁnancial  constraints,  so  there  are
ew  cross-sectional  data  from  other  countries  that  can  be
ompared  with  the  results  of  the  present  study.  Recent  data
rom  the  US  Centers  for  Disease  Control  (CDC)  indicate  that,
lthough  more  than  two  thirds  of  American  adults  had  under-
one  cholesterol  screening  within  the  previous  5  years,  more
han  13%  had  elevated  total  cholesterol  in  2009—2010  [19].
esides,  in  the  EURIKA  study,  conducted  across  many  Euro-
ean  countries,  a  large  proportion  of  outpatients  in  primary
revention  had  cardiovascular  risk  factors  that  remained
ncontrolled  [20]. Overall,  these  results  combine  to
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Table  2  Proportion  of  subjects  in  whom  LDL-cholesterol  target  was  not  achieved,  according  to  level  of  risk  as  assessed
by  the  French  and  ESC  guidelines.
Level  of  risk  (LDL-cholesterol
target)
Overall  (n  =  4609)  Subjects  not  receiving
lipid-lowering  therapy
(n  =  3663)
Subjects  receiving
lipid-lowering  therapy
(n  =  946)
Level  of  risk  according  to  French
guidelines  [4]
No associated  risk  factorsa
(5.7  mmol/L  =  2.2  g/L)
20/1615  (1.2)
[0.7—1.8]
16/1507  (1.1)  [0.5—1.6]  4/108  (3.7)  [0.1—7.3]
1  associated  risk  factora
(4.9  mmol/L  =  1.9  g/L)
124/1248  (9.9)
[8.3—11.6]
110/1038  (10.6)  [8.7—12.5]  14/210  (6.7)  [3.3—10.0]
2  associated  risk  factorsa
(4.1  mmol/L  =  1.6  g/L)
208/760  (27.4)
[24.2—30.5]
172/552  (31.2)  [27.3—35.0]  36/208  (17.3)  [12.2—22.5]
≥  3  associated  risk  factorsa
(3.4  mmol/L  =  1.3  g/L)
99/178  (55.6)
[48.3—62.9]
76/124  (61.3)  [52.7—69.9]  23/54  (42.6)  [29.4—55.8]
High  risk  (2.6  mmol/L  =  1  g/L)  667/808  (82.5)
[79.9—85.2]
408/442  (92.3)  [89.8—94.8]  259/366  (70.8)  [66.1—75.4]
Level  of  risk  according  to  ESC
guidelines  [2]
Low  risk  (3  mmol/L  =  1.15  g/L)  1784/2364  (75.5)
[73.7—77.2]
1650/2187  (75.4)  [73.6—77.3]  134/177  (75.7)  [69.4—82.0]
Moderate  risk
(3 mmol/L  =  1.15  g/L)
898/1075  (83.5)
[81.3—85.7]
699/795  (87.9)  [85.7—90.2]  199/280  (71.1)  [65.8—76.4]
High  risk  (2.6  mmol/L  =  1  g/L)  610/650  (93.8)
[92.0—95.7]
449/467  (96.1)  [94.4—97.9]  161/183  (88.0)  [83.3—92.7]
Very  high  risk
(1.8  mmol/L  =  0.7  g/L)
498/520  (95.8)
[94.0—97.5]
209/214  (97.7)  [95.6—99.7]  289/306  (94.4)  [91.9—97.0]
Data are expressed as n/n (%) [95% conﬁdence interval]. ESC: European Society of Cardiology; LDL: low-density lipoprotein.
a ‘‘Associated’’: number of risk factors except high LDL-cholesterol, as deﬁned in the French guidelines [4].  After direct standardization
for age and sex, using the 2009 French population as reference, the percentages and 95% conﬁdence intervals were as follows: French
guidelines (lowest to highest risk level): 1.2% [0.7—1.8%]; 9.7% [8.1—11.3%]; 28.0% [24.8—31.3%]; 56.9%; 82.2% (for the last two levels,
conﬁdence intervals could not be estimated because of strata with single sampling unit); ESC guidelines (lowest to highest risk level):
.8% [
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l75.2% [73.5—77.0%]; 83.4% [81.1—85.7%]; 94.0% [92.1—95.9%]; 95
uggest  that  hypercholesterolaemia  often  remains  inad-
quately  controlled,  regardless  of  the  country  that  is
onsidered  (France,  Europe  or  the  USA).
In  our  study,  approximately  10%  of  subjects  with  one  asso-
iated  risk  factor,  particularly  those  who  were  not  receiving
ipid-lowering  therapy,  did  not  reach  the  relatively  con-
ervative  LDL-cholesterol  target  of  less  than  4.9  mmol/L
1.9  g/L)  recommended  in  the  French  guidelines.  This  is  a
ause  for  concern,  given  that  the  French  recommendations
re  less  stringent  than  those  of  the  ESC,  and  suggests  that
ore  intensive  therapy  is  necessary  to  achieve  even  rela-
ively  high  targets.  Furthermore,  most  young  subjects  with
DL-cholesterol  concentrations  greater  than  5.7  mmol/L
2.2  g/L)  are  likely  to  have  familial  hypercholesterolaemia;
n  this  case  an  LDL-cholesterol  target  of  5.7  mmol/L  (2.2  g/L)
ill  maintain  an  elevated  residual  cardiovascular  risk.  In
ontrast,  in  the  ESC  guidelines,  people  with  familial  hyper-
holesterolaemia  are  considered  to  be  at  high  risk,  with
 recommended  LDL-cholesterol  concentration  of  less  than
.6  mmol/L  (1  g/L)  [2,3].
In  addition,  a  majority  of  participants  with  multiple  risk
actors,  or  those  who  were  considered  to  be  at  high  risk
ccording  to  the  French  guidelines,  did  not  reach  their
ecommended  targets.  This  might  suggest  that  treatments
iven  to  these  subjects  were  insufﬁcient  to  reach  the
t
t
t
u94.0—97.6%].
ecommended  goals  and  that  more  intensive  lipid-lowering
herapies  are  needed.  However,  it  might  also  suggest  that
he  level  of  risk  in  these  subjects  was  not  estimated  accu-
ately.  The  EURIKA  study  emphasizes  that  time  constraints,
ack  of  perceived  usefulness  and  inadequate  knowledge  are
arriers  preventing  physicians  from  using  global  risk  assess-
ent  tools  in  primary  prevention  [21]. In  accordance  with
his  hypothesis,  we  found  that  the  proportion  of  uncon-
rolled  subjects  was  signiﬁcantly  lower  in  participants  with
ocumented  cardiovascular  disease  (68.7%)  than  in  high-risk
rimary  prevention  participants  (87.1%),  who  may  not  have
een  identiﬁed  as  being  at  high  risk  by  their  general  practi-
ioner.  In  particular,  people  with  a  10-year  absolute  risk  of
HD  greater  than  20%  may  have  not  been  recognized.  One
hould,  however,  keep  in  mind  that  estimation  of  10-year
bsolute  risk  of  CHD  with  the  Framingham  equation  tends  to
verestimate  risk  in  the  French  population  [22].
An  important  result  of  our  study  is  the  reduction  in  LDL-
holesterol  required  to  meet  target.  With  the  exception  of
eople  identiﬁed  as  being  at  high  risk  by  the  French  guide-
ines,  a large  majority  of  uncontrolled  participants  without
reatment  required  reductions  in  LDL-cholesterol  of  less
han  30%  to  reach  the  recommended  targets.  This  means
hat  a  low  dose  of  a  generic  statin  would  be  adequate  in  most
ntreated  primary  prevention  subjects,  whereas  statins  with
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Table  3 Reductions  in  LDL-cholesterol  required  to  meet  targets  recommended  in  French  or  ESC  guidelines  in  subjects  who  were  not  receiving  lipid-lowering  therapy
and  did  not  reach  their  recommended  LDL-cholesterol  target.
LDL-C  concentration
(mmol/L;  g/L)
Reduction  required
to meet  target  (%)
Subjects  requiring  a  given  reduction  to  meet  target
<  30%  reduction 30—49%  reduction  ≥  50%  reduction
Level  of  risk  according  to  French  guidelines  [4]
No  associated  risk  factorsa (n  =  16)  6.23 ±  0.65;  2.41  ±  0.25  6.6 (1.6—9.7) 16 (100)  0 0
1  associated  risk  factora (n  =  110)  5.41 ±  0.54;  2.09  ±  0.21  6.6 (3.2—12.4) 109 (99.1)  1  (0.9) 0
2  associated  risk  factorsa (n  =  172)  4.79 ±  0.61;  1.85  ±  0.24  10.1 (5.0—18.3) 159 (92.4)  13  (7.6) 0
≥  3  associated  risk  factorsa (n  =  76)  4.02 ±  0.47;  1.56  ±  0.18  15.4 (8.6—20.2) 69 (90.8)  7  (9.2) 0
High  risk  (n  =  408)  4.06  ±  0.82;  1.57  ±  0.32  36.0  (24.5—43.3)  157  (38.5)  215  (52.7)  36  (8.8)
Level  of  risk  according  to  ESC  guidelines  [2]
Low  risk  (n  =  1650)  3.90  ±  0.63;  1.51  ±  0.24  21.7  (11.9—31.2)  1193  (72.3)  457  (27.7)  0
Moderate  risk  (n  =  699) 4.02 ±  0.65;  1.56  ±  0.25  24.6  (16.1—33.2)  455  (65.1)  244  (34.9)  0
High  risk  (n  =  449) 4.27  ±  1.06;  1.65  ±  0.41  36.3  (25.3—46.6)  154  (34.3)  211  (47.0)  84  (18.7)
Very  high  risk  (n  =  209) 3.69  ±  0.91;  1.43  ±  0.35  50.2  (40.7—58.4)  27  (12.9)  77  (36.8)  105  (50.2)
Data are expressed as mean ± standard deviation, median (interquartile range) or number (%). ESC: European Society of Cardiology; LDL: low-density lipoprotein.
a ‘‘Associated’’: number of risk factors except high LDL-cholesterol, as deﬁned in the French guidelines [4].
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Table  4 Reductions  in  LDL-cholesterol  required  to  meet  targets  recommended  in  French  or  ESC  guidelines  in  subjects  who  were  receiving  lipid-lowering  therapy  and
did  not  reach  their  recommended  LDL-cholesterol  target.
LDL-C  concentration
(mmol/L;  g/L)
Reduction  required
to meet  target  (%)
Subjects  requiring  a  given  reduction  to  meet  target
<  30%  reduction 30—49%  reduction  ≥  50%  reduction
Level  of  risk  according  to  French
guidelines  [4]
No  associated  risk  factorsa (n  =  4)  6.86  ±  0.55;  2.66  ±  0.21  16.6  (11.0—22.5)  4  (100)  0  0
1  associated  risk  factora (n  =  14)  5.58  ±  0.61;  2.16  ±  0.23  9.6  (2.9—16.3)  14  (100)  0  0
2  associated  risk  factorsa (n  =  36)  4.83  ±  0.64;  1.87  ±  0.25  11.3  (5.5—20.0)  35  (97.2)  1  (2.8)  0
≥  3  associated  risk  factorsa (n  =  23)  4.01  ±  0.74;  1.55  ±  0.29  9.8  (5.0—22.3)  20  (87.0)  3  (13.0)  0
High  risk  (n  =  259)  3.53  ±  0.69;  1.37  ±  0.27  23.5  (14.2—32.8)  170  (65.6)  81  (31.3)  8  (3.1)
Level  of  risk  according  to  ESC
guidelines  [2]
Low  risk  (n  =  134)  3.88  ±  0.67;  1.50  ±  0.26  20.5  (10.4—31.5)  98  (73.1)  36  (26.9)  0
Moderate  risk  (n  =  199)  3.79  ±  0.63;  1.47  ±  0.24  18.1  (9.7—28.7)  155  (77.9)  44  (22.1)  0
High  risk  (n  =  161)  3.80  ±  1.02;  1.47  ±  0.39  28.3  (15.4—36.9)  88  (54.7)  58  (36.0)  15  (9.3)
Very  high  risk  (n  =  289)  3.03  ±  0.76;  1.17  ±  0.30  39.7  (24.7—47.8)  93  (32.2)  141  (48.8)  55  (19.0)
Data are expressed as mean ± standard deviation, median (interquartile range) or number (%). ESC: European Society of Cardiology; LDL: low-density lipoprotein.
a ‘‘Associated’’: number of risk factors except high LDL-cholesterol, as deﬁned in the French guidelines [4].
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a  greater  LDL-cholesterol-lowering  effect  might  be  more
appropriate  in  high-risk  patients  requiring  a  larger  reduction
to  meet  the  target  or  in  patients  in  whom  LDL-cholesterol
remains  uncontrolled  despite  treatment.
One  might  be  surprised  by  the  discrepancies  existing
between  French  and  European  guidelines.  The  ﬁrst  dif-
ference  is  related  to  risk  assessment,  with  the  European
deﬁnition  of  high  and  very  high  risk  being  much  broader,
including  all  diabetics,  people  with  moderate  chronic  kid-
ney  disease  and  those  with  one  markedly  elevated  single
risk  factor,  whereas  these  situations  are  not  categorized
as  high  risk  in  the  French  guidelines.  The  second  differ-
ence  is  related  to  the  cholesterol  goals,  which  are  much
more  stringent  in  the  European  guidelines.  For  instance,
the  goal  is  3  mmol/L  (1.15  g/L)  for  the  lowest  risk  group,
while  concentrations  up  to  3.4  mmol/L  (1.30  g/L)  are  con-
sidered  acceptable  for  people  with  three  associated  risk
factors  in  the  French  guidelines.  The  consequence  of  these
differences  is  that  a  larger  proportion  of  candidates  should
receive  a  drug  treatment  when  European  guidelines  are
applied.  Studies  comparing,  at  the  population  level,  the
medical  and  the  economic  impact  of  these  two  strategies
of  risk  assessment  and  risk  management  are  sorely  lack-
ing.  Such  studies  are  obviously  very  complicated  to  conceive
because  of  the  multitude  of  confounding  biases  that  have  to
be  controlled.  Two  key  questions  are  thus  to  be  answered:
do  French  criteria  miss  the  identiﬁcation  of  some  high-risk
subjects  (e.g.  those  with  familial  hypercholesterolaemia),
who  consequently  may  be  inappropriately  managed?;  and
are  European  goals  too  stringent,  leading  to  the  excessive
and  unnecessary  treatment  of  some  low-risk  subjects?  Being
demanding  among  low-risk  subjects  requires  that  affordable
means  can  be  proposed  at  the  population  level  for  lowering
cholesterol.  Besides,  this  should  not  distract  practitioners
from  appropriately  controlling  high-risk  subjects,  a  point
that  has  to  remain  a  priority.
Study limitations
Our  study  does  have  a  number  of  limitations.  It  was  con-
ducted  in  three  contrasting  areas  of  France,  rather  than
nationwide,  and  inclusion  was  restricted  to  subjects  aged
35—74  years.  Thus,  the  study  population  may  not  be  truly
representative  of  the  general  French  population.  Further-
more,  the  possibility  of  selection  bias  cannot  be  excluded.
The  participants  had  a  relatively  high  average  level  of  edu-
cation  and  further  bias  could  arise  if  sicker  members  of  the
population  were  unable  to  attend  the  hospital  to  participate
in  the  study.  It  is  therefore  possible  that  the  study  population
was  healthier  and  better  educated  than  the  French  general
population.  A  further  limitation  of  the  study  is  that  only  one
measurement  of  risk  factors  was  made  in  each  participant.
Finally,  some  misclassiﬁcation  of  the  level  of  participants’
cardiovascular  risk  may  have  arisen  because  familial  hyperc-
holesterolaemia  and  diabetes  target  organ  damage  were  not
recorded  (microalbuminuria,  neuropathy  and  retinopathy
were  missing).  Besides,  10-year  cardiovascular  risk  was  esti-
mated  irrespective  of  the  use  of  lipid-lowering  drugs.  Conse-
quently,  risk  was  underestimated  in  people  with  a  long  past
history  of  elevated  cholesterol  without  drug  treatment  and
in  those  who  stopped  drug  treatment  after  the  present  study.101
onclusions
n  summary,  this  study  has  shown  that,  in  a  majority  of  pri-
ary  prevention  candidates  with  multiple  risk  factors  and
n  most  high-risk  subjects,  LDL-cholesterol  targets  recom-
ended  by  the  French  guidelines  are  not  being  achieved  in
rance.  This  might  be  attributed,  in  part,  to  the  fact  that
igh-risk  subjects  without  documented  cardiovascular  dis-
ase  may  not  be  recognized  as  being  at  high  risk.  There  is
herefore  a  strong  case  for  better  screening  of  subjects  with
espect  to  their  level  of  cardiovascular  risk  and  for  intensify-
ng  lipid-lowering  therapy  whenever  necessary,  with  the  aim
f  meeting  the  French  guideline  targets  in  the  ﬁrst  instance.
he  study  has  also  shown  that  the  more  stringent  targets
f  the  European  guidelines  are  not  being  achieved  in  most
ases.
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